0001793229-26-000046
SEC filingQ1 revenue grew modestly to $244.7M driven by Data iSight strength despite surprise bill services attrition, but operating income declined 31.9% to $6.6M amid cost pressures while net loss widened slightly to -$73.6M from higher interest on increased indebtedness.
Claritev Corporation (CTEV) reported Q1 FY2026 results showing revenue growth tempered by profitability challenges and elevated cash needs in its role as a leading provider of data analytics and technology-enabled cost management solutions to the healthcare industry.
Revenue rose 5.8% year-over-year to $244.7 million from $231.3 million, as detailed in Management's Discussion and Analysis. This increase stemmed primarily from strength in the Data iSight segment, though partially offset by declines in surprise bill services due to client and program attrition. This dynamic underscores the company's dependence on key product momentum amid competitive healthcare market pressures.
Operating income declined sharply by 31.9% to $6.6 million from $9.7 million, yielding a slim 2.7% operating margin. The erosion reflects heightened cost dynamics not fully detailed in core metrics but consistent with the business's technology-enabled operations, where investments in analytics and end-to-end solutions can pressure near-term profitability.
Cash flow from operations reflected deepening usage at -$45.8 million, compared to -$30.1 million in the prior-year quarter, signaling working capital strains inherent in healthcare services delivery. Capital expenditures climbed to $46.8 million from $38.9 million, focused on sustaining technology infrastructure, resulting in free cash flow of -$92.5 million. These outflows underscore the capital-intensive nature of maintaining data analytics platforms and revenue integrity tools.